研究の成果

原発性胆汁性胆管炎（PBC）

1. Gerussi A, Verda D, Bernasconi DP, et al. Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver Int 2022 Mar;42(3):615-627. https://pubmed.ncbi.nlm.nih.gov/34951722/
2. Matsumoto K, Ohfuji S, Abe M, et al. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: A multicenter case-control study. J Gastroenterol. 2022 Jan;57(1):19-29. https://pubmed.ncbi.nlm.nih.gov/34796398/
3. Fujinaga Y, Namisaki T, Takaya H, et al. Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. Medicine (Baltimore). 2021 Oct 1;100(39):e27403. https://pubmed.ncbi.nlm.nih.gov/34596167/
4. Cordell HJ, Fryett JJ, Ueno K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol. 2021 Sep;75(3):572-581. https://pubmed.ncbi.nlm.nih.gov/34033851/
5. Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-fee survival in patients with primary biliary cholangitis. J Hepatol, 2021 Sep;75(3):565-571. https://pubmed.ncbi.nlm.nih.gov/33882268/
6. Asselta R, Paraboschi EM, Gerrusi A, et al. X chromosome contribution to the genetic architecture of primary biliary cholangitis. Gastroenterology. 2021 Jun;160(7):2483-2495. https://pubmed.ncbi.nlm.nih.gov/33675743/
7. Arase Y, Matsumoto K, Anzai K, et al. Clinicopathological features of autoimmune hepatitis with IgG4-positive plasma cell infiltration. Dig Dis. 2021;39(3):225-233. https://pubmed.ncbi.nlm.nih.gov/32731217/
8. Kimura NN, Takamura M, Takeda N, et al. Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. Hepatol Int. 2021 Apr;15(2):437-443. https://pubmed.ncbi.nlm.nih.gov/33861397/
9. Takamura M, Matsuda Y, Kimura N, et al. Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016 Hepatol Res. 2021 Feb;51(2):166-175. https://pubmed.ncbi.nlm.nih.gov/33126288/
10. Kawata K, Joshita S, Shimoda S, et al. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatol Res. 2021 Jan;51(1):80-89. https://pubmed.ncbi.nlm.nih.gov/33080094/
11. Namisaki T, Fujinaga Y, Moriya K, et al. The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. Hepatol Res. 2021 Jan;51(1):31-38. https://pubmed.ncbi.nlm.nih.gov/33210415/
12. Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021 Jan;27(1):58-69. https://pubmed.ncbi.nlm.nih.gov/33291862/
13. Ito T, Ishigami M, Morooka H, et al. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep. 2020 Oct 20;10(1):17812. https://pubmed.ncbi.nlm.nih.gov/33082429/
14. Yagi M, Matsumoto K, Komori A, et al., on behalf of Japan PBC Study Group (JPBCSG). A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver Int, 2020 Aug;40(8):1926-1933. https://pubmed.ncbi.nlm.nih.gov/32438508/
15. Furukawa M, Moriya K, Nakayama J, et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol Res. 2020 Jul;50(7):840-852. https://pubmed.ncbi.nlm.nih.gov/32346970/
16. Joshita S, Yamashita Y, Sugiura A, et al. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. J Gastroenterol Hepatol. 2020 Jul;35(7):1208-1214. https://pubmed.ncbi.nlm.nih.gov/31724755/